News Overview

Amidst the slew of positive macro data flows, how did the stock markets perform?

It was probably a classic case of some of the year end fiscal deficit pressures of FY24 being carried forward

Alembic now has a total of 205 ANDA approvals from the USFDA, comprising 179 final approvals and 26 tentative approvals.

The company's EBITDA margin increased from 15.2% in FY21 to 19.7% in FY23, while ROCE increased from 5.5% to 16.6% and ROE increased from 1.0% to 16.3% over the same time.

Lupin has already accounted for the fine in previous financial reports, ensuring no impact on the current year’s profit and loss statement.

"The project is anticipated to cost ₹846.66 crore. The project is planned to be completed in 15 months from the date of PPA execution," it stated.

In addition, the company received orders for 80 Vande Bharat trains and 20 super fast gun mounts for military ships, with contractual deliveries beginning in June 2025.

These changes aim to strengthen the link between cash and F&O markets and enhance investor protection.

Market breadth was mixed with more advancing shares (1,929) than declining ones (1,449).

The stock has gained a total of 23% in the last one year, and 20% since the beginning of the year.